How to buy Atreca stock (BCEL)

Atreca is a biotechnology business based in the US. Atreca shares (BCEL) are listed on the PINK and all prices are listed in US Dollars. Atreca employs 90 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Atreca stock

Buy Atreca stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Atreca stock price (PINK: BCEL)

Use our graph to track the performance of BCEL stocks over time.

Atreca shares at a glance

• Key figures

Information last updated 2024-07-25.

52-week range	$0.05 - $0.44
50-day moving average more info button	$0.09
200-day moving average more info button	$0.20
Wall St. target price	$2.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.50

Atreca financials

Gross profit TTM	$0
Return on assets TTM	-51.2%
Return on equity TTM	-182.7%
Profit margin	0%
Book value	$0.27
Market Capitalization more info button	$3.6 million

TTM: trailing 12 months

Atreca share dividends

We're not expecting Atreca to pay a dividend over the next 12 months.

Have Atreca's shares ever split?

Atreca's shares were split on a 1:6 basis on 6 June 2019 . So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Atreca shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Atreca shares which in turn could have impacted Atreca's share price.

Atreca share price volatility

Over the last 12 months, Atreca's shares have ranged in value from as little as $0.052 up to $0.4448. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Atreca's is 1.026. This would suggest that Atreca's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Atreca overview

Atreca, Inc. , a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria.

Frequently asked questions

null
What percentage of Atreca is owned by insiders or institutions?
Currently 2.682% of Atreca shares are held by insiders and 8.385% by institutions. How many people work for Atreca?
Latest data suggests 90 work at Atreca. When does the fiscal year end for Atreca?
Atreca's fiscal year ends in December. Where is Atreca based?
Atreca's address is: 835 Industrial Road, South San Francisco, CA, United States, 94070 What is Atreca's ISIN number?
Atreca's international securities identification number is: US04965G1094 What is Atreca's CUSIP number?
Atreca's Committee on Uniform Securities Identification Procedures number is: 04965G109